Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Beximco Pharmaceuticals Limited Sponsored GDR RegS ( (GB:BXP) ).
Beximco Pharmaceuticals PLC, a leading Bangladeshi generic drug producer and contract manufacturer for multinational pharmaceutical companies, operates globally with a broad portfolio of dosage forms and maintains internationally certified manufacturing sites. The company employs over 6,000 staff and focuses on expanding its presence across continents by providing access to contemporary medicines.
The company has provided an update on two writ petitions before the High Court Division of the Supreme Court of Bangladesh, both challenging actions by the Bangladesh Securities and Exchange Commission regarding the appointment of nine additional independent non-executive directors to its board and an order to hold a board meeting to onboard them. Hearings on these petitions are now scheduled to commence after the court’s vacation period from 15 March 2026 to 18 April 2026, extending the timeline for resolving the governance dispute and leaving the board composition issue pending for stakeholders and regulators.
More about Beximco Pharmaceuticals Limited Sponsored GDR RegS
Beximco Pharmaceuticals PLC is a Bangladesh-based manufacturer and exporter of generic medicines and active pharmaceutical ingredients, serving markets in more than 50 countries. Its extensive portfolio spans tablets, capsules, injectables, inhalers, insulins, and other delivery systems, supported by state-of-the-art facilities certified by regulators in the U.S., Europe, Australia, Canada, GCC and Latin America.
Average Trading Volume: 84,567
Technical Sentiment Signal: Buy
Learn more about BXP stock on TipRanks’ Stock Analysis page.